section 823(a) and determined that the registration of Organichem Corporation to manufacture the listed controlled substances is consistent with the public interest at this time. DEA has investigated Organichem Corporation to ensure that the company's registration is consistent with the public interest. This investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed is granted.

Dated: July 3, 2003.

## Laura M. Nagel,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 03–18475 Filed 7–18–03; 8:45 am]

BILLING CODE 4410-09-M

#### DEPARTMENT OF JUSTICE

#### **Drug Enforcement Administration**

## Manufacturer of Controlled Substances; Notice of Registration

By Notice dated March 21, 2003, and published in the **Federal Register** on April 9, 2003, (68 FR 17408), Siegfried (USA) Inc., Industrial Park Road, Pennsville, New Jersey 08070, made application by renewal to the Drug Enforcement Administration to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Amphetamine (1100)	
Oxycodone (9143)	

The firm plans to manufacture the listed controlled substances for distribution as bulk products to its customers.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, section 823(a) and determined that the registration of Siegfried (USA) Inc. to manufacture the listed controlled substance is consistent with the public interest at this time. DEA has investigated Siegfried (USA) Inc. to ensure that the company's registration is consistent with the public interest. This investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted.

Dated: July 2, 2003.

#### Laura M. Nagel,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 03–18476 Filed 7–18–03; 8:45 am] **BILLING CODE 4410–09–M** 

## **DEPARTMENT OF JUSTICE**

### **Drug Enforcement Administration**

# Manufacturer of Controlled Substances; Notice of Registration

By Notice dated March 21, 2003, and published in the **Federal Register** on April 9, 2003, (68 FR 17405), Syva Company, Dade Behring Inc., Regulatory Affairs Department El–310, 20400 Mariana Avenue, Cupertino, California, 95014, made application by letter to the Drug Enforcement Administration to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Tetrahydrocannabinols (7370)	
Ecgonine (9180)	
Morphine (9300)	

The firm plans to produce bulk products used for the manufacture of reagents and drug calibrator/controls, DEA exempt products.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, section 823(a) and determined that the registration of Syva Company, Dade Behring Inc. to manufacture the listed

controlled substances is consistent with the public interest at this time. DEA has investigated Syva Company, Dade Behring Inc. to ensure that the company's registration is consistent with the public interest. This investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted.

Dated: July 2, 2003.

### Laura M. Nagel,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 03–18478 Filed 4–18–03; 8:45 am]
BILLING CODE 4410–09–M

#### **DEPARTMENT OF JUSTICE**

#### **Federal Bureau of Investigation**

## Agency Information Collection Activities: Proposed Collection; Comments Requested

ACTION: 30-Day Notice of Information Collection Under Review: Return A— Monthly Return of Offenses Known to the Police and Supplement to Return A—Monthly Return of Offenses Known to the Police.

The Department of Justice (DOJ), Federal Bureau of Investigations, has submitted the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. This proposed information collection was previously published in the **Federal Register** Volume 68, Number 93, page 25907 on May 14, 2003, allowing for a 60 day comment period.

The purpose of this notice is to allow for an additional 30 days for public comment until August 20, 2003. This process is conducted in accordance with 5 CFR 1320.10.

Written comments and/or suggestions regarding the items contained in this notice, especially the estimated public burden and associated response time,